Tag:
Merck
Latest Headlines
Latest Headlines
Merck marks another failure in elusive hunt for Parkinson's disease drugs
Merck has cut one of most advanced efforts to develop a new therapy for Parkinson's disease. Its Phase III clinical trials of preladenant for the prevalent neurological disorder failed to beat placebo, prompting the U.S. drug giant ($MRK) to halt extension studies of the experimental A2A receptor agonist and abandon plans to file for regulatory approvals for the treatment.
UPDATED: FDA panel backs low-dose rollout of Merck's sleep drug suvorexant
A panel of experts assembled by the FDA has given Merck a boost in its quest for an approval of the sleep drug suvorexant.
Merck to buy $5B in stock from Goldman Sachs in jump-start for repurchase plan
Generic competition, sales woes and R&D disappointments have put revenue on the decline and Merck in hot water, with the pharma giant earlier this month promising to buy back as much as $15 billion in shares. And yesterday, the company started in on a big chunk of that buyback, inking a deal to buy $5 billion of its own shares from Goldman Sachs.
Does pharma spend more on marketing than R&D? A numbers check
So, do drug companies really spend more money on marketing than on R&D? In the Pipeline takes a look at that contention, and the cold hard facts are these: Probably not. But it's hard to tell for sure.
JVs like Pfizer, Hisun hookup provide Chinese companies shot at Western markets
Joint ventures with Chinese companies have been seen as a way for Big Pharma to get better traction in the exploding China market. But it is not a one-way street. Chinese companies see the tie-ups as a way to build their own capabilities and begin to tap lucrative Western markets.
FDA: Merck's sleep drug suvorexant effective, but safety issues draw heavy flak
FDA staffers found clear evidence to prove that Merck's blockbuster drug candidate suvorexant is quite effective in promoting sleep, but the internal review cites multiple safety issues for the high doses studied in clinical trials.
Australian judge kills Merck Vioxx class action settlement
A federal judge in Australia has put the kibosh on a half-million-dollar settlement over ill effects of Merck's ($MRK) painkiller Vioxx, a drug that has spawned billions of dollars in litigation.
Daktari Diagnostics reels in $7M as it preps for Scotland expansion
Daktari Diagnostics reeled in another $7 million in equity financing, an amount likely to help fuel the company's overall expansion as well as the construction of a new plant in Scotland for its point-of-care-HIV tests.
Merck targets docs with revamped U.K. website and healthcare apps
Merck's U.K. group has raised its level of play in an industry-wide competition for the attention of physicians as they use the Internet.
Merck execs' bogeymen: Animal-rights, disease activists, plus laid-off workers
What keeps Merck's security staff up at night? Animal rights activists and laid-off workers, apparently.
